<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563872</url>
  </required_header>
  <id_info>
    <org_study_id>13455</org_study_id>
    <nct_id>NCT03563872</nct_id>
  </id_info>
  <brief_title>Enhancing Systems of Care to Improve Hypertension Guideline Implementation</brief_title>
  <official_title>Enhancing Systems of Care to Improve Hypertension Guideline Implementation to Communities With Health Disparities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective cluster randomized trial testing a systems-level strategy to
      implement current American Heart Association hypertension guidelines in African American
      communities at risk for cardiovascular related health disparities. The trial will take place
      within an integrated health system serving Detroit and will assess blood pressure control
      over one year's time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will randomize 12 clinics within the Henry Ford Health System to two arms. The
      first arm will be comparison clinics that continue to use existing team-based strategies for
      hypertension management. The second arm will be intervention clinics. These clinics will have
      enhancements to existing team-based hypertension management. The first enhancement is
      clinical decision support based in the electronic health record. The second enhancement is
      improved protocols to implement telehealth prescribing that is nurse-led.

      The trial will enroll participants through an urban emergency department. Participants will
      be assigned to one of these 12 clinics and continue study activities for 1 year. Clinicians
      at the clinics will manage blood pressure. Study specific visits will occur at 3, 6, 9, and
      12 months. Primary outcome assessment is 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date type="Anticipated">February 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>mean change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Intensity</measure>
    <time_frame>12 months</time_frame>
    <description>Calculated therapeutic intensity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>mean change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>mean change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Congruence</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of clinical encounters in which treatment is congruent with guidelines</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>12 months</time_frame>
    <description>within trial cost and long-term projected costs compared to QALY</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Team-based care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enhanced team-based care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intervention</intervention_name>
    <description>Enhancements to team-based care include clinical decision support and improved protocols for telehealth prescribing.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active Comparator</intervention_name>
    <description>Usual, team-based care</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt;18 years) African Americans

          -  Lacks established primary care for BP management

          -  History of HTN

          -  SBP â‰¥ 140 mmHg

        Exclusion Criteria:

          -  Pregnancy

          -  Need for hospitalization from ED

          -  Serious comorbid conditions

          -  Alcohol or drug dependence

          -  Suspected resistant HTN

          -  Anticipated poor-adherence to study designated primary care clinic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Joseph Miller, MD</investigator_full_name>
    <investigator_title>Senior Staff</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>team-based</keyword>
  <keyword>guidelines</keyword>
  <keyword>implementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

